A Phase 3, multicenter, single-arm, open label study of the efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in the Treatment of Patients with Congenital Hemophilia A with Factor VIII Inhibitors Undergoing Surgical or Other Invasive Procedures İNHİBİTÖRLÜ HEMOFİLİ A HASTASINDA DOMUZ FAKTÖR VIII İLE MİNÖR CERRAHİ


Creative Commons License

Sarper N. (Executive) , Zengin E. , Aylan Gelen S., Omay O.

Other Supported Projects, 2019 - 2019

  • Project Type: Other Supported Projects
  • Begin Date: August 2019
  • End Date: September 2019

Project Abstract

Feasibility Assessment for: A Phase 3, multicenter, single-arm, open label study of the efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in the Treatment of Patients with Congenital Hemophilia A with Factor VIII Inhibitors Undergoing Surgical or Other Invasive Procedures

We used the product in a minor surgery (port-catheter insertion) and completed the study succesfully without any complication.